[Method of complex therapy of chronic cystitis]

Area of Science:

• Urology
• Pharmacology
• Gastroenterology

Background:

• Chronic recurrent cystitis (HC) significantly impacts women's quality of life.
• Standard treatments for HC often have limited long-term efficacy.
• Investigating novel therapeutic agents is crucial for improving HC management.

Purpose of the Study:

• To evaluate the efficacy of hydroxyethyldimethyldihydropyrimidine (Xymedone) in treating chronic recurrent cystitis in women.
• To assess Xymedone's impact on bladder mucosa regeneration and remission duration.

Main Methods:

• A study involving 60 women diagnosed with chronic recurrent cystitis.
• 30 patients received standard treatment plus Xymedone (500 mg thrice daily for 30 days) after local therapy.
• Control group (30 patients) received standard treatment only; cystoscopies monitored bladder mucosa recovery.

Main Results:

• Xymedone treatment led to faster bladder mucosa regeneration and reduced low urinary tract symptoms (LUTS) compared to the control group.
• After 30 days, patients on Xymedone showed normalized laboratory parameters and improved bladder capacity.
• No recurrence of HC was observed in the Xymedone group during a two-year follow-up, versus 51% in the control group.

Conclusions:

• Hydroxyethyldimethyldihydropyrimidine (Xymedone) is effective in accelerating bladder mucosa healing post-treatment for recurrent cystitis.
• Xymedone significantly extends the duration of persistent remission in patients with chronic recurrent cystitis.
• Xymedone represents a promising therapeutic option for managing chronic recurrent cystitis.